WEKO3
アイテム
Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients.
http://hdl.handle.net/10422/00013070
http://hdl.handle.net/10422/000130700754f323-d45c-4a92-8284-544158a7da9b
| Item type | 学術雑誌論文 / Journal Article(1) | |||||
|---|---|---|---|---|---|---|
| 公開日 | 2021-09-15 | |||||
| タイトル | ||||||
| タイトル | Severe Skin Disorders Due to Sorafenib Use After Nivolumab Treatment in Renal Cell Carcinoma Patients. | |||||
| 言語 | ||||||
| 言語 | eng | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | Sorafenib | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | immunotherapy | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | nivolumab | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | renal cell carcinoma | |||||
| キーワード | ||||||
| 言語 | en | |||||
| 主題Scheme | Other | |||||
| 主題 | skin disorder | |||||
| 資源タイプ | ||||||
| 資源タイプ識別子 | http://purl.org/coar/resource_type/c_6501 | |||||
| 資源タイプ | journal article | |||||
| アクセス権 | ||||||
| アクセス権 | metadata only access | |||||
| アクセス権URI | http://purl.org/coar/access_right/c_14cb | |||||
| 著者 |
KOIDE, Hiroyoshi
× KOIDE, Hiroyoshi× NODA, Satoshi× YOSHIDA, Tetsuya× KAGEYAMA, Susumu× TERAMURA, Kazuya× KATO, Takeshi× KAWAUCHI, Akihiro× FUJIMOTO, Noriki× TERADA, Tomohiro |
|||||
| 著者別名 |
小出, 博義
× 小出, 博義× 野田, 哲史× 吉田, 哲也× 影山, 進× 寺村, 和也× 加藤, 威× 河内, 明宏× 藤本, 徳毅× 寺田, 智祐 |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Background: We report two cases in which severe skin disorders developed during sorafenib treatment in patients with renal cell carcinoma (RCC) who had previously received nivolumab. |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Case report: Case 1: A 50-year-old man with RCC received nivolumab as the fifth-line therapy followed by sorafenib as the sixth-line therapy. On day 15 of sorafenib administration, the patient was hospitalized with systemic erythema multiforme, acne-like skin rash, and hand-foot syndrome. Case 2: A 40-year-old man with RCC received nivolumab as the second-line therapy followed by sorafenib as the fifth-line treatment. On day 12 of sorafenib administration, the patient was hospitalized with an acne-like skin rash and hand-foot syndrome. The skin disorders in the two cases improved within 2-3 weeks after sorafenib discontinuation and the start of treatment with topical and oral steroids. |
|||||
| 抄録 | ||||||
| 内容記述タイプ | Abstract | |||||
| 内容記述 | Conclusion: When using sorafenib in patients previously treated with nivolumab, close attention should be paid to the onset of serious skin disorders. |
|||||
| 書誌情報 |
en : In vivo (Athens, Greece) 巻 35, 号 5, p. 2969-2974, 発行日 2021-09 |
|||||
| 出版者 | ||||||
| 出版者 | International Institute of Anticancer Research | |||||
| ISSN | ||||||
| 収録物識別子タイプ | ISSN | |||||
| 収録物識別子 | 1791-7549 | |||||
| PMID | ||||||
| 識別子タイプ | PMID | |||||
| 関連識別子 | 34410996 | |||||
| DOI | ||||||
| 識別子タイプ | DOI | |||||
| 関連識別子 | https://doi.org/10.21873/invivo.12591 | |||||
| 関連名称 | 10.21873/invivo.12591 | |||||
| 権利 | ||||||
| 権利情報 | © 2021 International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved. | |||||
| 資源タイプ | ||||||
| 内容記述タイプ | Other | |||||
| 内容記述 | Journal Article | |||||
